NDAORALPOWDER
Approved
Jul 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEPHIENCE (sepiapterin) is an oral powder formulation approved by the FDA on July 28, 2025, as a small-molecule therapeutic developed by PTC Therapeutics. The specific indication and mechanism of action are not publicly detailed in available data, but sepiapterin is a precursor in the tetrahydrofolate pathway with potential applications in neurological or metabolic disorders. This product represents PTC's expansion in rare disease therapeutics.
Growth15.5 years to LOE
Early-stage commercial growth phase with no current competitive pressure; brand team is actively expanding and recruiting across multiple functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Started Mar 2024
56 enrolled
Phenylketonuria
Career Relevance
SEPHIENCE offers 20 active job opportunities spanning commercial, clinical operations, R&D, and regulatory functions, reflecting PTC's aggressive post-launch build-out. Joining this team provides exposure to early-stage commercialization of a novel rare disease product with no competitive threats and strong patent protection.
Director
Worked on SEPHIENCE at PTC Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.